Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Be Biopharma, Inc.

News headline image
Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces Appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform at ASH 2024
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces Upcoming Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
From Be Biopharma, Inc.
Via Business Wire
News headline image
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at 2023 Cell & Gene Meeting on the Mesa
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma to Present at the Jefferies Healthcare Conference
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces Oral Presentation on Precise Genome Engineering of Human B Cells to Express Diverse Therapeutic Proteins at American Society of Gene & Cell Therapy 26th Annual Meeting
From Be Biopharma, Inc.
Via Business Wire
News headline image
Be Biopharma Announces First Scientific Disclosures and New Preclinical Data Supporting the Advancement of B Cell Medicines at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Be Biopharma, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.